Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SRDX's Cash to Debt is ranked higher than
98% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. SRDX: No Debt )
SRDX' s 10-Year Cash to Debt Range
Min: 50.6   Max: No Debt
Current: No Debt

Equity to Asset 0.94
SRDX's Equity to Asset is ranked higher than
97% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. SRDX: 0.94 )
SRDX' s 10-Year Equity to Asset Range
Min: 0.74   Max: 0.96
Current: 0.94

0.74
0.96
Interest Coverage No Debt
SRDX's Interest Coverage is ranked higher than
86% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. SRDX: No Debt )
SRDX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 8
Z-Score: 32.53
M-Score: -2.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 33.53
SRDX's Operating margin (%) is ranked higher than
98% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. SRDX: 33.53 )
SRDX' s 10-Year Operating margin (%) Range
Min: -20.11   Max: 51.75
Current: 33.53

-20.11
51.75
Net-margin (%) 27.02
SRDX's Net-margin (%) is ranked higher than
98% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. SRDX: 27.02 )
SRDX' s 10-Year Net-margin (%) Range
Min: -35.08   Max: 32.59
Current: 27.02

-35.08
32.59
ROE (%) 16.17
SRDX's ROE (%) is ranked higher than
89% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. SRDX: 16.17 )
SRDX' s 10-Year ROE (%) Range
Min: -13.66   Max: 21.78
Current: 16.17

-13.66
21.78
ROA (%) 14.88
SRDX's ROA (%) is ranked higher than
96% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. SRDX: 14.88 )
SRDX' s 10-Year ROA (%) Range
Min: -12.38   Max: 20.24
Current: 14.88

-12.38
20.24
ROC (Joel Greenblatt) (%) 111.09
SRDX's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. SRDX: 111.09 )
SRDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18.81   Max: 181
Current: 111.09

-18.81
181
Revenue Growth (%) -1.80
SRDX's Revenue Growth (%) is ranked higher than
65% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. SRDX: -1.80 )
SRDX' s 10-Year Revenue Growth (%) Range
Min: -24.6   Max: 57.8
Current: -1.8

-24.6
57.8
» SRDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SRDX Guru Trades in Q1 2013

Jim Simons 264,200 sh (+19.85%)
Bill Frels 754,340 sh (+0.13%)
Chuck Royce 773,300 sh (-16.06%)
Joel Greenblatt 43,239 sh (-18.82%)
» More
Q2 2013

SRDX Guru Trades in Q2 2013

Paul Tudor Jones 13,700 sh (New)
Jim Simons 397,538 sh (+50.47%)
Joel Greenblatt 59,954 sh (+38.66%)
Bill Frels 751,440 sh (-0.38%)
Chuck Royce 733,300 sh (-5.17%)
» More
Q3 2013

SRDX Guru Trades in Q3 2013

Steven Cohen 9,329 sh (New)
Jim Simons 425,738 sh (+7.09%)
Chuck Royce 733,300 sh (unchged)
Paul Tudor Jones Sold Out
Bill Frels 750,540 sh (-0.12%)
Joel Greenblatt 54,907 sh (-8.42%)
» More
Q4 2013

SRDX Guru Trades in Q4 2013

Mario Gabelli 15,617 sh (New)
Jim Simons 455,138 sh (+6.91%)
Chuck Royce 733,300 sh (unchged)
Steven Cohen Sold Out
Bill Frels 745,690 sh (-0.65%)
Joel Greenblatt 46,744 sh (-14.87%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2013-12-31 New Buy$21.61 - $25.135 $ 22.8-3%15617
Joel Greenblatt 2013-06-30 Add 38.66%0.01%$19.74 - $27.55 $ 22.8-9%59954
Joel Greenblatt 2012-12-31 Reduce -25.79%0.03%$17.45 - $22.03 $ 22.815%53262
Joel Greenblatt 2012-12-31 Reduce -25.79%0.03%$17.45 - $22.03 $ 22.815%53262
Joel Greenblatt 2012-09-30 Add 60.21%0.04%$15.38 - $20.78 $ 22.826%71768
Mario Gabelli 2012-09-30 Sold Out 0.03%$15.38 - $20.78 $ 22.826%0
PRIMECAP Management 2012-06-30 Sold Out 0.0015%$13.6 - $17.22 $ 22.852%0
Joel Greenblatt 2012-03-31 Add 200.69%0.04%$13.86 - $16.06 $ 22.866%44610
Joel Greenblatt 2011-12-31 New Buy0.03%$8.86 - $14.99 $ 22.8100%14836
PRIMECAP Management 2011-12-31 Reduce -73.57%$8.86 - $14.99 $ 22.8100%66000
Mario Gabelli 2011-03-31 Add 93.72%$11.53 - $13.18 $ 22.886%167468
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.50
SRDX's P/E(ttm) is ranked higher than
66% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.50 vs. SRDX: 22.50 )
SRDX' s 10-Year P/E(ttm) Range
Min: 8.5   Max: 687.94
Current: 22.5

8.5
687.94
P/B 3.50
SRDX's P/B is ranked higher than
58% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. SRDX: 3.50 )
SRDX' s 10-Year P/B Range
Min: 0.98   Max: 7.77
Current: 3.5

0.98
7.77
P/S 5.89
SRDX's P/S is ranked lower than
62% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. SRDX: 5.89 )
SRDX' s 10-Year P/S Range
Min: 2.16   Max: 16.43
Current: 5.89

2.16
16.43
PFCF 21.30
SRDX's PFCF is ranked higher than
51% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.36 vs. SRDX: 21.30 )
SRDX' s 10-Year PFCF Range
Min: 8.44   Max: 511.5
Current: 21.3

8.44
511.5
EV-to-EBIT 16.10
SRDX's EV-to-EBIT is ranked higher than
65% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. SRDX: 16.10 )
SRDX' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 253.6
Current: 16.1

4.5
253.6
Shiller P/E 57.50
SRDX's Shiller P/E is ranked lower than
63% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. SRDX: 57.50 )
SRDX' s 10-Year Shiller P/E Range
Min: 16.62   Max: 158.8
Current: 57.5

16.62
158.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.50
SRDX's Price/Net Cash is ranked lower than
75% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. SRDX: 18.50 )
SRDX' s 10-Year Price/Net Cash Range
Min: 3.9   Max: 700
Current: 18.5

3.9
700
Price/Net Current Asset Value 14.20
SRDX's Price/Net Current Asset Value is ranked lower than
65% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. SRDX: 14.20 )
SRDX' s 10-Year Price/Net Current Asset Value Range
Min: 3.7   Max: 763
Current: 14.2

3.7
763
Price/Tangible Book 4.00
SRDX's Price/Tangible Book is ranked higher than
64% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. SRDX: 4.00 )
SRDX' s 10-Year Price/Tangible Book Range
Min: 1.26   Max: 18.49
Current: 4

1.26
18.49
Price/DCF (Projected) 1.60
SRDX's Price/DCF (Projected) is ranked higher than
64% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. SRDX: 1.60 )
SRDX' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 4.62
Current: 1.6

0.53
4.62
Price/Median PS Value 0.80
SRDX's Price/Median PS Value is ranked higher than
86% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. SRDX: 0.80 )
SRDX' s 10-Year Price/Median PS Value Range
Min: 0.33   Max: 6.46
Current: 0.8

0.33
6.46
Price/Graham Number 2.00
SRDX's Price/Graham Number is ranked higher than
60% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. SRDX: 2.00 )
SRDX' s 10-Year Price/Graham Number Range
Min: 0.9   Max: 12.63
Current: 2

0.9
12.63
Earnings Yield (Greenblatt) 6.20
SRDX's Earnings Yield (Greenblatt) is ranked higher than
68% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. SRDX: 6.20 )
SRDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 22
Current: 6.2

0.4
22
Forward Rate of Return (Yacktman) 2.62
SRDX's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. SRDX: 2.62 )
SRDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.8   Max: 62.5
Current: 2.62

0.8
62.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
SurModics, Inc. is a Minnesota Corporation. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company's core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility characteristics and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. It partners with many of the emerging medical device, pharmaceutical and life science companies to develop and commercialize innovative products designed to improve patient outcomes. In the product lines in which The Company competes (protein stabilization reagents, substrates, recombinant autoimmune antigens and surface chemistry technologies), it faces an array of competitors ranging from large manufacturers with multiple business lines to small manufacturers that offer a limited selection of products. Although its drug delivery and surface modification technologies themselves are not directly regulated by the Food and Drug Administration, the medical devices, pharmaceutical and biotechnology products incorporating its technologies are subject to FDA regulation.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide